Interventional Cardiology Devices – Market Insights – Europe Part 2

With the impact of, and recovery from, the COVID-19 pandemic coming to an end, the European IC device market will shortly witness a return to prepandemic growth trends. Shifting preference toward several new approaches, such as FFR, IVUS, DCBs for complex PCIs, specialty balloons, and radial access approaches, along with new positive clinical, will fuel market growth in the European IC device market, thus impacting the position of the current market leaders going forward.

This Medtech 360 Report provides comprehensive data and analysis on the state of the market for IC devices in Europe from 2019 through 2032.

The DES segment is a highly competitive space, with the leading companies continuing to launch updates to their flagship devices.

Has there been any change in position between the three major competitors in the highly lucrative DES device market?

What competitive strategies are the major competitors implementing to gain share in this market?

How will BRS development impact the coronary stent market over the forecast period?

Emerging technologies designed to diagnose and treat complex PCIs will influence the IC device market landscape in Europe.

How are DCBs going to be adopted going forward?

What is the impact of the latest generation of alternative coronary physiology modalities such as resting index or imaging-based FFR_angio and FFR_CT on the patient and procedure in cardiac catheterization labs?

How will recent clinical evidence impact the adoption of IVUS and OCT?

How will the emergence of alternative FFR modalities affect the FFR pressure guidewire market?

What is the status and expected impact of emerging techniques like coronary lithotripsy?

How will this impact the small and mid-sized emerging companies in the IC device market?

The European IC device market has been impacted by the COVID-19 pandemic.

What is the recovery outlook for 2022 and going forward?